To systematically analyze the literature to assess the economic and health-related quality of life (HRQoL) impact of adverse events (AEs) related to the addition of protease inhibitors (PI) to standard of care (SOC) for the treatment of hepatitis C (HCV). METHODS: A literature search (2000-Present) was conducted to identify and analyze clinical trials for PI triple therapy (PITT = PI + SOC) and SOC (PEGIFN/RBV for 48 weeks). HRQoL and safety data were synthesized by study design, sample characteristics, and AEs. Economic and resource use data were synthesized in an economic analysis of AEs in PITT vs. SOC. Costs (2009) were derived from published literature. RESULTS: Twenty-three SOC and 7 PITT trials were identifi ed. Statistically signifi cant (p = or <0.05) changes from baseline were most often seen in trials of SOC in the following domains: vitality, depression, physical limitations, and fatigue. The following 4 PITT-related AEs could be linked to HRQoL domains: anemia and depression were linked to fatigue and vitality, and headache and rash were linked to physical limitations. In terms of economic impacts, the costs to manage a PITT-related episode of anemia, depression, diarrhea, and rash were $4825, $2837, $566, and $633, respectively. The average AE cost in PITT ranged from $1732 to $3578. Corresponding costs in SOC ranged from $1608 to $2229. The treatment costs of PITT-related AEs were 30% (range 8-60%) higher than the cost of treating SOC-related AEs. CONCLUSIONS: The costs to manage PITT-related AEs appear higher than the costs of SOC-related AEs. Since PITT is associated with higher AE rates, it can also be expected to result in worse HRQoL. Gaps in symptom burden assessment with existing instruments also exist. Future studies should incorporate the economic burden of AEs and the appropriate use of HCV-validated instruments to capture potential HRQoL differences among treatment strategies. CHC is a curable disease since patients achieving SVR can remain virus-free. We evaluated CHC treatment for effi cacy (SVR) and long-term effects on reduction of disease progression to advanced stages, improvement in quality of life, and reduction of health care costs. The objective was to estimate the burden of disease and impact of SVR in CHC patients on lifetime life-years (LY), QALYs and costs using a Markov model and published literature. METHODS: A systematic literature review identifi ed publications reporting the cost-effectiveness of antiviral therapies in CHC (November 2009). PubMed, CRD and Health Technology Assessment reports were searched. We selected all cost-effectiveness (CE) studies with a similar Markov structure including eight health states (SVR, mild/moderate CHC, compensated and decompensated cirrhosis, hepatocellular carcinoma [HCC], liver transplant and death). CE inputs were used to populate a Markov model to estimate average lifetime benefi ts and costs associated with SVR and non-SVR. Age of entry in the model was 40 years. Costs were updated to 2008 Great Britain Pounds (GBP). Discount rates for costs and outcomes were 3.5%. RESULTS: 893 unique references were retrieved and 14 articles met the inclusion criteria. Compared to non-SVR patients, the SVR group was consistently associated with more LYs (18.33, range [18.05;18.53] not according to the recommended ARV dosing guidelines were identifi ed in ARV regimens between lopinavir/ritonavir at PDD 1066.4 mg/264 mg and efavirenz at PDD 600 mg prescribed to patients 19 to 45 years. These regimens were mostly prescribed by general practitioners as compared to specialists. CONCLU-SIONS: There is need for more education of prescribers to be aware of the potential medication-prescribing errors associated with highly active antiretroviral therapy which could lead to treatment failures, development of resistance and DDIs. Varicella complications place a large burden on health care resources, however, varicella is preventable by mass vaccination with MMRV. The impact on complications of three MMRV programs were explored. METHODS: An age-structured dynamic model compared natural and breakthrough varicella following mass vaccination, to current cases. Age-specifi c complication rates (neurologic, cutaneous, pulmonary, other) were applied per case. MMRV replaced 80% of MMR over 1 year (basecase) compared to 100% of MMR with a catch-up in 11-13 year-olds ('catch up'). In an 'optimal' scenario, MMR coverage increased from 90% to 95% (1 st dose) and 60% to 90% (2 nd dose), MMRV replaced 100% MMR within 1 year with a catch-up in 10 year-olds. RESULTS: MMRV decreased varicella incidence and caused an age shift, however, many post-vaccination cases were breakthrough cases, believed to be milder and require less resource use. Prior to MMRV: highest varicella incidence (per million-person-years of total population) was among 1-4 year-olds (7,482 cases), with 355 complications (age-specifi c complication rate: 4.75%). Basecase: highest incidence among 10-14 year-olds (907 natural, 633 breakthrough), with 54 complications (age-specifi c rate: 3.53%); 85% lower versus 1-4 year-olds. 'Catch-up': highest incidence among 15-24 year-olds (161 natural, 398 breakthrough), with 49 complications (age-specifi c rate: 8.82%); 86% lower versus 1-4 year-olds. 'Optimal': highest incidence among 15-24 year-olds (22 natural, 80 breakthrough), with 9 complications; 97.5% lower versus 1-4 year-olds. Assuming breakthrough cases have 10% of complications of natural cases, the incidence in the basecase, catch-up and optimal scenarios becomes: 34, 18 and 3 complications respectively. Despite greater risks of complications in older age groups, the reduction in varicella cases signifi cantly reduced the incidence of complications. The ICER remained below c16,000 (direct costs). CONCLUSIONS: Mass varicella vaccination is predicted to signifi cantly reduce varicella and complication cases. As many vaccine era cases will be breakthrough; burden to patients and health care systems may be reduced further.
PIN2 ESTIMATED IMPACT OF SUSTAINED VIROLOGICAL RESPONSE (SVR) ON LIFE EXPECTANCY, QUALITY-ADJUSTED LIFE-YEARS (QALYS) AND LIFETIME COSTS IN CHRONIC HEPATITIS C (CHC) PATIENTS
CHC is a curable disease since patients achieving SVR can remain virus-free. We evaluated CHC treatment for effi cacy (SVR) and long-term effects on reduction of disease progression to advanced stages, improvement in quality of life, and reduction of health care costs. The objective was to estimate the burden of disease and impact of SVR in CHC patients on lifetime life-years (LY), QALYs and costs using a Markov model and published literature. METHODS: A systematic literature review identifi ed publications reporting the cost-effectiveness of antiviral therapies in CHC (November 2009). PubMed, CRD and Health Technology Assessment reports were searched. We selected all cost-effectiveness (CE) studies with a similar Markov structure including eight health states (SVR, mild/moderate CHC, compensated and decompensated cirrhosis, hepatocellular carcinoma [HCC] , liver transplant and death). CE inputs were used to populate a Markov model to estimate average lifetime benefi ts and costs associated with SVR and non-SVR. Age of entry in the model was 40 years. Costs were updated to 2008 Great Britain Pounds (GBP). Discount rates for costs and outcomes were 3.5%. RESULTS: 893 unique references were retrieved and 14 articles met the inclusion criteria. Compared to non-SVR patients, the SVR group was consistently associated with more LYs (18.33, range [18.05; 18.53] PDDs not according to the recommended ARV dosing guidelines were identifi ed in ARV regimens between lopinavir/ritonavir at PDD 1066.4 mg/264 mg and efavirenz at PDD 600 mg prescribed to patients 19 to 45 years. These regimens were mostly prescribed by general practitioners as compared to specialists. CONCLU-SIONS: There is need for more education of prescribers to be aware of the potential medication-prescribing errors associated with highly active antiretroviral therapy which could lead to treatment failures, development of resistance and DDIs. Varicella complications place a large burden on health care resources, however, varicella is preventable by mass vaccination with MMRV. The impact on complications of three MMRV programs were explored. METHODS: An age-structured dynamic model compared natural and breakthrough varicella following mass vaccination, to current cases. Age-specifi c complication rates (neurologic, cutaneous, pulmonary, other) were applied per case. MMRV replaced 80% of MMR over 1 year (basecase) compared to 100% of MMR with a catch-up in 11-13 year-olds ('catch up'). In an 'optimal' scenario, MMR coverage increased from 90% to 95% (1 st dose) and 60% to 90% (2 nd dose), MMRV replaced 100% MMR within 1 year with a catch-up in 10 year-olds. RESULTS: MMRV decreased varicella incidence and caused an age shift, however, many post-vaccination cases were breakthrough cases, believed to be milder and require less resource use. Prior to MMRV: highest varicella incidence (per million-person-years of total population) was among 1-4 year-olds (7,482 cases), with 355 complications (age-specifi c complication rate: 4.75%). Basecase: highest incidence among 10-14 year-olds (907 natural, 633 breakthrough), with 54 complications (age-specifi c rate: 3.53%); 85% lower versus 1-4 year-olds. 'Catch-up': highest incidence among 15-24 year-olds (161 natural, 398 breakthrough), with 49 complications (age-specifi c rate: 8.82%); 86% lower versus 1-4 year-olds. 'Optimal': highest incidence among 15-24 year-olds (22 natural, 80 breakthrough), with 9 complications; 97.5% lower versus 1-4 year-olds. Assuming breakthrough cases have 10% of complications of natural cases, the incidence in the basecase, catch-up and optimal scenarios becomes: 34, 18 and 3 complications respectively. Despite greater risks of complications in older age groups, the reduction in varicella cases signifi cantly reduced the incidence of complications. The ICER remained below c16,000 (direct costs). CONCLUSIONS: Mass varicella vaccination is predicted to signifi cantly reduce varicella and complication cases. As many vaccine era cases will be breakthrough; burden to patients and health care systems may be reduced further.
PIN4 IMPACT OF MMRV MASS VACCINATION WITH OR WITHOUT A CATCH UP PROGRAM ON THE INCIDENCE OF VARICELLA COMPLICATIONS IN FRANCE

PIN5 HOW LONGITUDINAL PATIENT RECORDS CAN HELP PUBLIC HEALTH AUTHORITIES IN THE MANAGEMENT OF RAPIDLY GROWING EPIDEMICS? THE EXPERIENCE OF FLU A/H1N1 IN FRANCE
Toussi M, Pertus D, Antonio M, Robain M CSD, Boulogne, Billancourt, France OBJECTIVES: In the context of an epidemic, public health authorities need to have real time information of the disease propagation to make appropriate and timely decisions. We present our experience in using centralized electronic patient records in the early detection and follow-up of Flu A/H1N1 epidemic in France. METHODS: We used Longitudinal Patient Data (LPD), which is a dynamic centralized database of more than 1.3 million anonymous patient records uploaded regularly by a network of 1300 representative general practitioners and pediatricians in France. The trends of seasonal infl uenza, Flu A/H1N1 and fl u-like syndrome diagnoses are traced and compared with the reports published by Sentinel Network, a group of trained physicians set up by public authorities. RESULTS: The trends of seasonal infl uenza, Flu A/ H1N1, and fl u-like syndrome obtained from LPD database show a very close similarity with those published by Sentinel Network (Pearson's correlation coeffi cient = 0.97). The seasonal pattern of the incidence of infl uenza and fl u-like syndrome were less similar between 2009 and 2008 (Pearson's correlation coeffi cient = 0.60), which can be explained by an over declaration of all kinds of fl u by the doctors during the second half of 2009. There was also a close similarity between seasonal Flu, approved Flu A/ H1N1, and fl u-like syndrome trends with a peak incidence in late November 2009. CONCLUSIONS: The LPD data matched very closely the results published by the
